Physician profile
David T May
NPI 1316937352
$3,500.19
in general payments reported to CMS, 2019-2025
22 companies · $1,589 in 2025
The $1,589 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $25.22 · 2021: $16.00 · 2022: $268 · 2023: $304 · 2024: $1,026 · 2025: $1,589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,844 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,844.02 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $843.35 | 2022-2025 | |
| Janssen Biotech, INC. | $483.48 | 2023-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $282.14 | 2024-2025 | Entyvio, Eohilia |
| Qol Medical, LLC | $219.54 | 2025 | Sucraid |
| Madrigal Pharmaceuticals | $211.61 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $197.36 | 2023-2025 | Xifaxan, Trulance, Plenvu |
| Covidien Lp | $194.00 | 2019 | |
| Ardelyx, INC. | $172.85 | 2024-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $169.24 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $124.32 | 2020-2024 | Linzess |
| Fujifilm Healthcare Americas Corporation | $118.57 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $79.60 | 2024-2025 | Dupixent |
| Cook Medical LLC | $77.48 | 2019 | |
| Pentax of America, INC. | $72.50 | 2020-2025 | Pentax Medical, C2 Cryoballoon Focal Controller, C2 Cryoballoon |
| Olympus America INC. | $51.30 | 2023-2024 | Visiglide, Endoclot Phs |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $46.40 | 2023-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $41.92 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $38.81 | 2025 | Iqirvo |
| Celltrion USA INC. | $24.52 | 2025 | Vegzelma |
| Genzyme Corporation | $21.28 | 2023 | |
| Boston Scientific Corporation | $16.25 | 2025 | Captivator II |
| Pfizer INC. | $13.67 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David May listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.